What is Lipoprotein(a) and Why Does It Matter?
Lipoprotein(a), or Lp(a), is a lipid particle produced by the liver. Its levels are largely genetically determined and not significantly influenced by lifestyle factors like diet or exercise. Numerous studies have confirmed that elevated Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and major adverse cardiovascular events. It is estimated that approximately 20% of the global population has elevated Lp(a) levels, putting hundreds of millions at potential cardiovascular risk.
The Current Treatment Gap: A Huge Unmet Medical Need
Despite growing recognition of Lp(a)'s role in disease progression, there are currently no approved therapies specifically designed to lower Lp(a). With the global dyslipidemia market projected to reach approximately $18.7 billion by 2032, oral small molecule inhibitors of Lp(a) hold significant opportunities while addressing a substantial unmet need in clinical practice.
ISM0900: An Innovative Oral Candidate Designed by AI
Insilico Medicine has announced the nomination of ISM0900 as a preclinical candidate (PCC). This is a potent, AI-driven, highly selective, orally available small molecule inhibitor of Lp(a), designed to block the assembly of Lp(a) from the beginning. Its development was enabled by Chemistry42, Insilico's proprietary generative chemistry platform, which integrates more than 40 carefully selected models. By analyzing the crystal structure of the target-small molecule complex, the team performed de novo fragment generation and structural reconstruction, ultimately discovering ISM0900 as a highly selective candidate molecule.
Promising Preclinical Data: Potent, Fast, and Safe
In preclinical studies, ISM0900 demonstrated potent and selective inhibition at nanomolar-level activity, with several key advantages:
- Potent Lp(a) reduction: Achieved an 83.9% reduction in Lp(a), with consistent lowering observed throughout the study period.
- Rapid onset: Reached peak effect by Day 4, with an onset time of less than 40% of available clinical-stage candidates.
- Oral convenience: Exhibits excellent oral pharmacokinetic properties, potentially improving patient adherence.
- Favorable safety profile: Shows wide safety margins and a projected lower efficacious human dose.
Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, stated: "ISM0900 represents an exciting advance in our cardiovascular pipeline, combining a novel AI-enabled structure with strong preclinical data. More importantly, the formation as an oral therapy may also offer important advantages for patients, including convenience and improved adherence."
How AI is Accelerating Drug Discovery?
As an AI-native biotechnology company, Insilico is redefining the efficiency of preclinical drug development. While traditional early-stage drug discovery typically takes 2.5 to 4 years, Insilico has consistently reached PCC nomination in an average of just 12 to 18 months, with only 60 to 200 molecules synthesized and tested per program. Since 2021, the company has nominated 33 PCCs, 13 of which have received IND approval or clearance. AI not only accelerates the discovery process but also improves the probability of success through more options produced by innovation at scale.
Cardiovascular diseases are deeply connected to aging, a challenge faced by all of us. Elevated Lp(a) represents an important and insufficiently addressed contributor to that risk. By enabling rapid design and optimization of novel molecules, AI helps us move faster in discovering new therapies. For those concerned about heart health, regular check-ups to understand your Lp(a) levels are crucial. You can use the Xiaoshu Health App, which syncs with Apple's [Health] app to track relevant metrics, helping you monitor and manage your cardiovascular health data over the long term.